David Shaw’s Beam Therapeutics BEAM Stock Holding History

David Shaw’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.48M	Buy	+130,577	New	+$3.94M	﹤0.01%	2494
2026 Q1	–	Sell	-27,935	Closed	-$774K	–	4546
2025 Q4	$774K	Buy	+27,935	New	+$713K	﹤0.01%	3694
2024 Q3	–	Sell	-8,721	Closed	-$204K	–	4532
2024 Q2	$204K	Buy	+8,721	New	+$214K	﹤0.01%	4065
2022 Q4	–	Sell	-43,995	Closed	-$2.1M	–	4863
2022 Q3	$2.1M	Buy	+43,995	New	+$2.51M	﹤0.01%	2965
2022 Q1	–	Sell	-17,269	Closed	-$1.38M	–	5530
2021 Q4	$1.38M	Sell	17,269 -41,974	-71%	-$3.59M	﹤0.01%	3672
2021 Q3	$5.16M	Buy	+59,243	New	+$5.95M	﹤0.01%	2077
2021 Q2	–	Sell	-6,196	Closed	-$494K	–	4748
2021 Q1	$496K	Buy	+6,196	New	+$589K	﹤0.01%	3508

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

David Shaw's BEAM Position: Q2 2026 in Review

David Shaw opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 130,577 shares worth $4.48M. The stake represents ﹤0.01% of the portfolio and ranks #2494 among its holdings. This is a return to the name: David Shaw previously reported a position in BEAM as recently as Q4 2025.

David Shaw first reported a position in BEAM in Q1 2021 and has held it in 7 quarters since. The position peaked at $5.16M in Q3 2021. 276 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

David Shaw held 130,577 shares of Beam Therapeutics worth $4.48M as of Q2 2026.
Beam Therapeutics was a new David Shaw position in Q2 2026.
Beam Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2494 holding.
David Shaw first reported a position in Beam Therapeutics in Q1 2021 and has held it in 7 quarters since.
David Shaw's Beam Therapeutics position peaked at $5.16M in Q3 2021.
276 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.